Ken Shimada

Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial

Yasuhide Yamada, Daisuke Takahari, Hiroshi Matsumoto et al. · The Lancet Oncology · 2013 · 253 citations

Medicine, Oncology, Pharmacology +12

Biweekly irinotecan plus cisplatin versus irinotecan alone as second-line treatment for advanced gastric cancer: A randomised phase III trial (TCOG GI-0801/BIRIP trial)

Katsuhiko Higuchi, Satoshi Tanabe, Ken Shimada et al. · European Journal of Cancer · 2014 · 82 citations

Medicine, Oncology, Pharmacology +11

ANGPTL3 is a novel biomarker as it activates ERK/MAPK pathway in oral cancer

Tomoyoshi Koyama, Katsunori Ogawara, Atsushi Kasamatsu et al. · Cancer Medicine · 2015 · 78 citations · Full text

Medicine, Cancer Biology, Oncology +14

Adjuvant therapy for gastric carcinoma patients in the past 15 years

Ken Shimada, Jaffer A. Ajani · Cancer · 1999 · 67 citations

Medicine, Oncology, Surgery +13

Identification of differentially expressed proteins in oral squamous cell carcinoma using a global proteomic approach

Hirofumi Koike, Katsuhiro Uzawa, Dai Nakashima et al. · International Journal of Oncology · 2005 · 62 citations

Medicine, Biochemistry, Oncology +17